Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Expanded QuantideX qPCR BCR-ABL Portfolio

Asuragen has launched a new CE-marked QuantideX qPCR BCR-ABL minor kit for identifying minor (e1a2) BCR-ABL fusion transcripts in patients with chronic myeloid leukemia. The new test joins the firm's existing FDA-cleared and CE-marked QuantideX qPCR BCR-ABL IS Kit that covers major (e13a2, e14a2) fusions.

The two kits can be combined in a streamlined and common workflow, and Asuragen said it is also expanding the capabilities of its QuantideX Reporter, analysis software, which accompanies the CE-marked QuantideX qPCR BCR-ABL IS Kit, to allow laboratories the ability to report CML patient disease burden on the International Scale after reviewing ABL1 copy number, in compliance with European LeukemiaNet guidelines.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.